Merck KGaA to Buy Bio-Techne for $11.3 Billion
Merck KGaA announced it will acquire Bio-Techne for $11.3 billion in cash, at $73 per share, representing a 24% premium. Bio-Techne stock jumped 21% in premarket trading on Thursday.
Key Numbers
Germany's Merck KGaA (XETRA: MRK) announced on Thursday it has agreed to acquire Bio-Techne (NASDAQ: TECH) for $11.3 billion in cash, according to a press release. Under the terms, Merck will pay $73 per share, a 24% premium over Bio-Techne's closing price on Wednesday.
Bio-Techne shares surged 21% in premarket trading to $70.95, reflecting investor confidence in the deal's completion.
Deal Details
| Item | Value |
|---|---|
| Total Value | $11.3 billion |
| Price per Share | $73 |
| Premium to Close | 24% |
| Payment Method | Cash |
| Acquirer | Merck KGaA (Germany) |
| Target | Bio-Techne (USA) |
Rationale
Merck aims to strengthen its foothold in the life sciences and diagnostics sectors. Bio-Techne's portfolio of research tools and reagents complements Merck's existing life science business.
Regulatory Hurdles
The deal is subject to regulatory approvals in the U.S. and Europe. No specific timeline for closing has been provided, but it is expected to take several months.
Stock Impact
Bio-Techne shares rallied in premarket trading, while Merck's stock remained relatively stable. Analysts view the acquisition as strategically sound given the complementary nature of the businesses.
Frequently Asked Questions
Found this useful? Share it